Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020. Abstract #231-OR will be available online from 14 June 2020.
The annual meeting of the ADA is the largest worldwide scientific meeting for clinicians and researchers in diabetes.
Oral Presentation #231-OR:
Phase I Study Investigating the PD, PK and Safety of AT247 in Comparison with NovoRapid® and Fiasp®
Presenting Author: Professor Thomas Pieber
Session: Insulin Therapies
Date and Time: Sunday, 14 June 2020, at 4.30pm US Central Time
AT247, an investigational novel meal-time insulin formulation, aims to significantly accelerate insulin absorption post injection to enable more effective management of blood glucose levels.
About the ADA Scientific Sessions
The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals around the world an exclusive opportunity to share ideas and gain knowledge about the recent advances in diabetes research, treatment, and care. Attendees will have access to more than 800 presentations and nearly 200 virtual sessions and lectures, take part in provocative and engaging exchanges with leading diabetes experts, and expand their professional networks.
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Notes to Editors
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
Mo PR Advisory www.mopradvisory.com
Mo Noonan Mob: +44 (0) 7876 444977